SCHEMBL5034433

SCHEMBL5034433

O=C(O)CNC(=O)c1cc2ccccc2c(-c2ccc(O)cc2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.48
EGLN1 Q9GZT9 10/20 0.46
FTO Q9C0B1 5/20 0.45
BBOX1 O75936 1/20 0.45
EGLN3 Q9H6Z9 1/20 0.45
KDM6B O15054 1/20 0.43
KDM5B Q9UGL1 1/20 0.42
KDM2A Q9Y2K7 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
DHODH Q02127 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4757074 0.84 HPGD (0.55) KDM4CEGLN1FTOBBOX1EGLN3
SCHEMBL3923469 0.81 KDM4C (0.46) KDM4CEGLN1FTOBBOX1KDM6B
SCHEMBL5030186 0.80 KDM4C (0.45) KDM4CEGLN1FTOBBOX1EGLN3
SCHEMBL4758413 0.80 EGLN1 (0.48) KDM4CEGLN1FTOBBOX1
SCHEMBL4984126 0.78 DHODH (0.40) DHODHMEN1KMT2A
SCHEMBL18427673 0.77 FTO (0.46) KDM4CEGLN1FTOEGLN3HDAC3
SCHEMBL18427667 0.77 EGLN1 (0.50) KDM4CEGLN1FTOBBOX1EGLN3
SCHEMBL18427662 0.74 FTO (0.46) EGLN1FTOEGLN3
SCHEMBL10985563 0.72 KDM4E (0.48) DHODHMEN1KMT2A
SCHEMBL1219655 0.72 KDM4C (0.64) KDM4CEGLN1FTOBBOX1EGLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893186-A2 IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT FIBROGEN, INC. (US) 2008-03-05 EP claimed
WO-2006133391-A2 IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT FIBROGEN, INC. (US) 2006-12-14 WO claimed
EP-1919463-A2 USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER FIBROGEN, INC. (US) 2008-05-14 EP disclosed
EP-1893186-A2 IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT FIBROGEN, INC. (US) 2008-03-05 EP disclosed
WO-2007146425-A2 COMPOUNDS AND METHODS FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA FIBROGEN, INC. (US) 2007-12-21 WO disclosed
WO-2007047194-A2 METHODS FOR TREATING MITF-RELATED DISORDERS DANA-FARBER CANCER INSTITUTE, INC. (US) 2007-04-26 WO disclosed
WO-2006138511-A2 USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER FIBROGEN, INC. (US) 2006-12-28 WO disclosed
WO-2006133391-A2 IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT FIBROGEN, INC. (US) 2006-12-14 WO disclosed
EP-1644336-A1 NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN FIBROGEN, INC. (US) 2006-04-12 EP disclosed
WO-2004108681-A1 NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN FIBROGEN, INC. (US) 2004-12-16 WO disclosed